A New Rapid-Acting Antidepressant

Cell. 2020 Apr 2;181(1):7. doi: 10.1016/j.cell.2020.02.033.

Abstract

The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

MeSH terms

  • Antidepressive Agents* / pharmacology
  • Antidepressive Agents* / therapeutic use
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Drug Approval*
  • GABAergic Neurons / drug effects
  • Humans
  • Ketamine* / pharmacology
  • Ketamine* / therapeutic use
  • Receptors, AMPA / metabolism
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*

Substances

  • Antidepressive Agents
  • Receptors, AMPA
  • Receptors, N-Methyl-D-Aspartate
  • Esketamine
  • Ketamine